IQ-AI Ltd
("IQ-AI" or the "Company")
IB awarded a $100,000 grant by the Musella Foundation
Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces that it has been awarded a $100,000 grant by the Musella Foundation For Brain Tumor Research & Information, Inc. The grant will help support the launch of the recently announced intermediate group expanded access program (iEAP). The iEAP will allow brain tumor patients access to oral (pill form) gallium maltolate (GaM) outside of the on-going phase 1 clinical trial on-going at the Medical College of Wisconsin (MCW).
The Musella Foundation provided an initial award towards the on-going phase 1 clinical trial being conducted at the Medical College of Wisconsin (MCW). Since then, IB has maintained and fostered a close relationship with The Musella Foundation.
"Our interest in this particular agent is growing. It appears to be extremely well tolerated and may possess clinical benefit for patients who have exhausted standard therapies," said Dr. Al Musella, Founder and President of The Musella Foundation.
The grant will be used to facilitate the iEAP including writing and submitting the study protocol, patient screening and on-boarding, and more.
"This iEAP will enable brain tumor patients with limited or no other treatment alternatives to gain access to oral GaM. We appreciate the support from the Musella Foundation and IQ-AI who helped make this happen," said Dr. Jennifer Connelly, MD, Professor of Neurology at MCW and co-PI of the trial.
--ENDS-
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
| IQ-AI Ltd Trevor Brown/Vinod Kaushal/Brett Skelly/Michael Schmainda Tel: 020 7469 0930 |
| Peterhouse Capital Limited (Financial Adviser and Broker) Lucy Williams/Heena Karani Tel: 020 7220 9797 |
About The Musella Foundation
The Musella Foundation For Brain Tumor Research & Information, Inc is a 501(C)3 nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research. Visit virtualtrials.org for more information.
About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.